Concepedia

Wengang Ge

WG

Statistics

Publications

6

Citations

530

H-Index

6

Active since

2006

Affiliations

Zhejiang University(Current)

First Affiliated Hospital Zhejiang University

Zhejiang Lab

Wengang Ge is an author at Zhejiang University specializing in cancer immunotherapy, oncology, and chimeric antigen receptor t-cell therapy.

Publications per year

2006–2022

6

Publications

6

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu, Yali Zhou, Mingming Zhang et al. · Clinical Cancer Research · 2021 · 274 citations · Full text

, , +17

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

Yongxian Hu, Yali Zhou, Mingming Zhang et al. · Cell Research · 2022 · 190 citations · Full text

, , +16

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang et al. · Blood · 2022 · 19 citations

, , +14

Early experiences on living donor liver transplantation in China: multicenter report

Xuehao Wang, Lünan Yan, Feng Zhang et al. · Chinese Medical Journal · 2006 · 19 citations · Full text

, , +16

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, Yali Zhou, Mingming Zhang et al. · Blood · 2020 · 15 citations

, , +14

1–5 of 6